Low dose colestipol in adolescents with familial hypercholesterolaemia

Archives of Disease in Childhood

Volumn 74, Issue 2, 1996, Pages 157-160

  Tonstad, S ^a   Sivertsen, M ^a   Aksnes, L ^b   Ose, L ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

Colestipol; Familial hypercholesterolaemia; Vitamins

Indexed keywords

25 HYDROXYVITAMIN D; ALPHA TOCOPHEROL; CAROTENOID; COLESTIPOL; FOLIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO;

ADOLESCENT; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HUMAN; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; VITAMIN BLOOD LEVEL;

EID: 0030020038     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/adc.74.2.157     Document Type: Article

References (29)

1. National Cholesterol Education Program. Report of the expert panel on blood cholesterol levels in children and adolescents. Pediatrics 1992; 89 (suppl): 525-84.
2. International Task Force for Prevention of Coronary Heart Disease. Prevention of coronary heart disease: scientific background and new clinical guidelines. Nutr Metab Cardiovasc Dis 1992; 2: 113-56.
3. Stein EA. Drug therapy in children and adolescents with familial hypercholesterolemia. Recent aspects of diagnosis and treatment of lipoprotein disorders: impact on prevention of atherosclerotic diseases. New York: Alan R Liss, 1988: 273-80.
4. West RJ, Lloyd JK. Long-term follow-up of children with familial hypercholesterolaemia treated with cholestyramine. Lancet 1980; ii: 873-5.
5. Schlierf G, Mrozik K, Heuck CC, et al. 'Low dose' colestipol in children, adolescents and young adults with familial hypercholesterolaemia. Atherosclerosis 1982; 41: 133-8.
6. Liacouras CA, Coates PM, Gallagher PR, et al. Use of cholestyramine in the treatment of children with familial combined hyperlipidemia. J Pediatr 1993; 122: 477-82.
7. Leren TP, Solberg K, Rødningen OK, et al. Two founder mutations in the LDL receptor gene in Norwegian familial hypercholesterolemia subjects. Atherosclerosis 1994; 111: 175-82.
8. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotcin cholesterol without the use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
9. Aksnes L. Simultaneous determination of retinol, alphatocopherol and 25-hydroxyvitamin D in human serum by high-performance liquid chromatography. J Pediatr Gastroenterol Nutr 1994; 18: 339-43.
10. Holick MF. The use and interpretation of assays for vitamin D and its metabolites. J Nutr 1990; 120: 1464-9.
11. Underwood BA. Methods for assessment of vitamin A status. J Nutr 1990; 120: 1459-63.
12. Thurnham DI, Davies JA, Crump BJ, et al. The use of different lipids to express serum tocopherol : lipid ratios for the measurement of vitamin E status. Ann Clin Biochem 1986; 23: 514-20.
13. West RJ, Lloyd JK. The effect of cholestyramine on intestinal absorption. Gut 1975; 16: 93-8.
14. West RJ, Lloyd JK. Use of cholestyramine in treatment of children with familial hypercholesterolaemia. Arch Dis Child 1973; 48: 370-4.
15. Farah JR, Kwiterovich PO, Neill CA. Dose-effect relation of cholestyramine in children and young adults with familial hypercholesterolaemia. Lancet 1977; i: 59-63.
16. Schwarz KB, Goldstein PD, Witztum JL, et al. Fat-soluble vitamin concentrations in hypercholesterolemic children treated with colestipol. Pediatrics 1980; 65: 243-50.
17. Schlierf G, Vogel G, Kohlmeier M, et al. Long term treatment of young patients with familial hypercholesterolemia with colestipol: plasma levels of minerals and vitamins. Klin Wochenschr 1985; 63: 802-6.
18. Norwegian Pharmaceutical Products Compendium 1995/96; 37: 673-4.
19. Stampfer MJ, Malinow MR, Willett WC, et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 1992; 268: 877-81.
20. Bailey LB. Folate status assessment. J Nutr 1990; 120: 1508-11.
21. Tsang RC, Roginsky MS, Mellies MJ, et al. Plasma 25-hydroxy-vitamin D in familial hypercholesterolemic children receiving colestipol resin. Pediatr Res 1978; 12: 980-2.
22. Glueck CJ, Tsang RC, Fallat RW, et al. Plasma vitamin A and E levels in children with familial type II hyperlipoproteinemia during therapy with diet and cholestyramine resin. Pediatrics 1974; 54: 51-5.
23. Glueck CJ, Fallat RW, Mellies M, et al. Pediatric familial type II hyperlipoproteinaemia therapy with diet and colestipol resin. Pediatrics 1976; 57: 68-74.
24. Gey KF, Puska P, Jordan P, et al. Inverse correlation between plasma vitamin E and mortality from ischemic heart disease in cross-cultural epidemiology. Am J Clin Nutr 1991; 53 (suppl): 326-34.
25. Riemersma RA, Wood DA, Macintyre CCA, et al. Risk of angina pectoris and plasma concentrations of vitamins A, C, and E and carotene. Lancet 1991; 337: 1-5.
26. Smith DK, Greene JM, Leonard SB, et al. Vitamin A in hypercholesterolemia. Am J Med Sci 1992; 304: 20-1.
27. Bresnike JF, Levy RI, Kelsey SF, et al. Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study. Circulation 1984; 69: 313-24.
28. Superko HR, Greenland P, Manchester RA, et al. Effectiveness of low-dose colestipol therapy in patients with moderate hypercholesterolemia. Am J Cardiol 1992; 70: 135-40.
29. Hansen D, Michaelsen KF, Skovby F. Growth during treatment of familial hypercholesterolemia. Acta Paediatr Scand 1992; 81: 1023-5.